The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part I - Blood pressure measurement, diagnosis and assesment of risk

Canadian Journal of Cardiology

Volumn 22, Issue 7, 2006, Pages 573-581

  Hemmelgarn, Brenda R ^a   McAlister, Finlay A ^b   Grover, Steven ^c   Myers, Martin G ^d   McKay, Donald W ^e   Bolli, Peter ^f   Abbott, Carlo ^g   Schiffrin, Ernesto I ^h   Honos, George ^h   Burgess, Ellen ^a   Mann, Karen ⁱ   Wilson, Thomas ^j   Penner, Brian ^k   Tremblay, Guy ^l   Milot, Alain ^m   Chockalingam, Arun ⁿ   Touyz, Rhian M ^o   Tobe, Sheldon W ^p  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c MONTREAL GENERAL HOSPITAL   (Canada)

^d SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^e MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^f Ambulatory Internal Medicine Teaching Clinic   (Canada)

^g QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^h MCGILL UNIVERSITY   (Canada)

ⁱ DALHOUSIE UNIVERSITY   (Canada)

^j UNIVERSITY OF SASKATCHEWAN   (Canada)

^k UNIVERSITY OF MANITOBA   (Canada)

^l LAVAL UNIVERSITY   (Canada)

^m UNIVERSITÉ LAVAL   (Canada)

ⁿ SIMON FRASER UNIVERSITY   (Canada)

^o OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^p UNIVERSITY OF TORONTO   (Canada)

more..

Author keywords

Blood pressure; Diagnosis; Guidelines; High blood pressure; Hypertension; Risk factors

Indexed keywords

ALCOHOL; ANABOLIC AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCINEURIN INHIBITOR; CENTRAL STIMULANT AGENT; COCAINE; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN; DECONGESTIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ERYTHROPOIETIN; GLYCYRRHIZA EXTRACT; MIDODRINE; MONOAMINE OXIDASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; SEX HORMONE; SODIUM CHLORIDE; TACROLIMUS; VASOCONSTRICTOR AGENT;

ATHEROSCLEROSIS; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; CANADA; CARDIOVASCULAR RISK; CONSENSUS; DIAGNOSTIC ACCURACY; ECHOCARDIOGRAPHY; EVIDENCE BASED PRACTICE; FOLLOW UP; HEALTH EDUCATION; HEALTH PROGRAM; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; HYPOKALEMIA; LABORATORY TEST; LIFESTYLE; MEDLINE; METHODOLOGY; PEER REVIEW; PHEOCHROMOCYTOMA; PRACTICE GUIDELINE; PUBLICATION; RENOVASCULAR HYPERTENSION; REVIEW; RISK ASSESSMENT; SLEEP APNEA SYNDROME; ADVISORY COMMITTEE; ARTICLE; MASS SCREENING; PATIENT EDUCATION; RISK FACTOR;

ADVISORY COMMITTEES; BLOOD PRESSURE DETERMINATION; CANADA; ECHOCARDIOGRAPHY; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; MASS SCREENING; PATIENT EDUCATION; PHEOCHROMOCYTOMA; RISK ASSESSMENT; RISK FACTORS;

EID: 33745713577     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0828-282X(06)70279-3     Document Type: Article

References (31)

1. Joffres MR, Hamet P, MacLean DR, L'italien GJ, Fodor G. Distribution of blood pressure and hypertension in Canada and the United States. Am J Hypertens 2001;14:1099-105.
2. Kannel WB. Blood pressure as a cardiovascular risk factor: Prevention and treatment. JAMA 1996;275:1571-6.
3. Yusuf S, Hawken S, Ounpuu S, et al; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet 2004;364:937-52.
4. McAlister FA, Levine M, Zarnke KB, et al; Canadian Hypertension Recommendations Working Group. The 2000 Canadian recommendations for the management of hypertension: Part one - therapy. Can J Cardiol 2001;17:543-59.
5. Zarnke KB, Levine M, McAlister FA, et al; Canadian Hypertension Recommendations Working Group. The 2000 Canadian recommendations for the management of hypertension: Part two - diagnosis and assessment of people with high blood pressure. Can J Cardiol 2001;17:1249-63.
6. Zarnke KB, McAlister FA, Campbell NR, et al; Canadian Hypertension Recommendations Working Group. The 2001 Canadian recommendations for the management of hypertension: Part one - Assessment for diagnosis, cardiovascular risk, causes and lifestyle modification. Can J Cardiol 2002;18:604-24.
7. McAlister FA, Zarnke KB, Campbell NR, et al; Canadian Hypertension Recommendations Working Group. The 2001 Canadian recommendations for the management of hypertension: Part two - Therapy. Can J Cardiol 2002;18:625-41.
8. Hemmelgarn BR, Zarnke KB, Campbell NR, et al; Canadian Hypertension Education Program, Evidence-Based Recommendations Task Force. The 2004 Canadian Hypertension Education Program recommendations for the management of hypertension: Part I - Blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol 2004;20:31-40.
9. Khan NA, McAlister FA, Campbell NR, et al; Canadian Hypertension Education Program. The 2004 Canadian recommendations for the management of hypertension: Part II - Therapy. Can J Cardiol 2004;20:41-54.
10. Hemmelgarn BR, McAllister FA, Myers MG, et al; Canadian Hypertension Education Program. The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1 - blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol 2005;21:645-56.
11. Khan NA, McAlister FA, Lewanczuk RZ, et al; Canadian Hypertension Education Program. The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II - Therapy. Can J Cardiol 2005;21:657-72.
12. Zarnke KB, Campbell NR, McAlister FA, Levine M; Canadian Hypertension Recommendations Working Group. A novel process for updating recommendations for managing hypertension: Rationale and methods. Can J Cardiol 2000;16:1094-102.
13. Mourad A, Carney S. Arm position and blood pressure: An audit. Intern Med J 2004;34:290-1.
14. Matthys J, De Meyere M, Mervielde I, et al. Influence of the presence of doctors-in-training on the blood pressure of patients: A randomised controlled trial in 22 teaching practices. J Hum Hypertens 2004;18:769-73.
15. Padwal R, Straus SE, McAlister FA. Evidence based management of hypertension. Cardiovascular risk factors and their effects on the decision to treat hypertension: Evidence based review. BMJ 2001;322:977-80.
16. Topol EJ, Lauer MS. The rudimentary phase of personalised medicine: Coronary risk scores. Lancet 2003;362:1776-7.
17. Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation 1991;83:356-62.
18. Deber RB, Kraetschmer N, Irvine J. What role do patients wish to play in treatment decision making? Arch Intern Med 1996;156:1414-20.
19. D'Agostino RB Sr, Grundy S, Sullivan LM, Wilson P; CHD Risk Prediction Group. Validation of the Framingham coronary heart disease prediction scores: Results of a multiple ethnic groups investigation. JAMA 2001;286:180-7.
20. D'Agostino RB, Russell MW, Huse DM, et al. Primary and subsequent coronary risk appraisal: New results from the Framingham study. Am Heart J 2000;139:272-81.
21. Grover SA, Paquet S, Levinton C, Coupal L, Zowall H. Estimating the benefits of modifying risk factors of cardiovascular disease: A comparison of primary vs secondary prevention. Arch Intern Med 1998;158:655-62.
22. Kothari V, Stevens RJ, Adler AI, et al. UKPDS 60: Risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke 2002;33:1776-81.
23. Stevens RJ, Kothari V, Adler AI, Stratton IM; United Kingdom Prospective Diabetes Study (UKPDS) Group. The UKPDS risk engine: A model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci (Lond) 2001;101:671-9.
24. Conroy RM, Pyorala K, Fitzgerald AP, et al; SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: The SCORE project. Eur Heart J 2003;24:987-1003.
25. Sawka AM, Prebtani AP, Thabane L, Gafni A, Levine M, Young WF Jr. A systematic review of the literature examining the diagnostic efficacy of measurement of fractionated plasma free metanephrines in the biochemical diagnosis of pheochromocytoma. BMC Endocr Disord 2004;4:2.
26. Bolli P, Myers M, McKay D; Canadian Hypertension Education Program. Applying the 2005 Canadian Hypertension Education Program recommendations: 1. Diagnosis of hypertension. CMAJ 2005;173:480-3.
27. Pickering TG, Gerin W, Schwartz AR. What is the white-coat effect and how should it be measured? Blood Press Monit 2002;7:293-300.
28. Mancia G. Reversed white-coat hypertension. Definition, mechanisms and prognostic implications. J Hypertens 2002;20:579-81.
29. Bobrie G, Chatellier G, Genes N, et al. Cardiovascular prognosis of "masked hypertension" detected by blood pressure self-measurement in elderly treated hypertensive patients. JAMA 2004; 291:1342-9.
30. Stergiou GS, Salgami EV, Tzamouranis DG, Roussias LG. Masked hypertension assessed by ambulatory blood pressure versus home blood pressure monitoring: is it the same phenomenon? Am J Hypertens 2005;18:772-8.
31. Devereux RB, Wachtell K, Gerdts E, et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 2004;292:2350-6.